CPT: 82947
Print Share

Test Details


  • Blood Sugar


Diagnose diabetes mellitus; evaluate disorders of carbohydrate metabolism including alcoholism; evaluate acidosis and ketoacidosis; evaluate dehydration, coma, hypoglycemia of insulinoma, neuroglycopenia. A fasting glucose ≥125 mg/dL on more than one occasion is adequate for the diagnosis of diabetes mellitus. An OGTT is not necessary in this setting. Infants, especially with tremor, cyanosis, convulsions, and respiratory distress should have stat glucose, particularly if there is maternal diabetes, postmaturity, asphyxia, hemolytic disease of the newborn, or possible sepsis. Babies too large or small for gestational age should also have glucose in the first 24 hours of life. Random blood sugars can be used to monitor therapy in diabetics or evaluate presence of insulinoma.1,2


Mild glucose impairment can exist with fasting glucose within the normal range. Measurement of plasma glucose without spinal fluid glucose can miss neuroglycopenia. To the extent that innovative new methods deviate from reference methods, such alternative techniques may be unreliable for certain patient care needs.3 Fingerstick glucose determination in shock are lower than venous glucose and are dangerously misleading.4



Reference Interval

65−99 mg/dL

Additional Information

Recent evidence revealed a diurnal variation in FPG, with mean FPG higher in the morning than in the afternoon, indicating that many cases of undiagnosed diabetes would be missed in patients seen in the afternoon. Glucose concentrations decrease ex vivo with time in whole blood because of glycolysis. The rate of glycolysis, reported to average 5% to 7% [~0.6 mmol/L (10 mg/dL)] per hour, varies with the glucose concentration, temperature, white blood cell count, and other factors. Glycolysis can be attenuated by inhibition of enolase with sodium fluoride (2.5 mg fluoride/mL of blood) or, less commonly, lithium iodoacetate (0.5 mg/mL of blood). These reagents can be used alone or, more commonly, with anticoagulants such as potassium oxalate, EDTA, citrate, or lithium heparin. Although fluoride maintains long-term glucose stability, the rate of decline of glucose in the first hour after sample collection in tubes with and without fluoride is virtually identical. (Note that leukocytosis will increase glycolysis even in the presence of fluoride if the white cell count is very high). After four hours, the glucose concentration is stable in whole blood for 72 hours at room temperature in the presence of fluoride. In separated, nonhemolyzed, sterile serum without fluoride, the glucose concentration is stable for fourteen days at 25°C and 4°C.

Glucose can be measured in whole blood, serum, or plasma, but plasma is recommended for diagnosis. The molality of glucose (ie, amount of glucose per unit water mass) in whole blood and plasma is identical. Although red blood cells are essentially freely permeable to glucose (glucose is taken up by facilitated transport), the concentration of water (kg/L) in plasma is ~11% higher than that of whole blood. Therefore, glucose concentrations in plasma are ~11% higher than whole blood if the hematocrit is normal. Glucose concentrations in heparinized plasma are reported to be 5% lower than in serum. The reasons for the latter difference are not apparent but may be attributable to the shift in fluid from erythrocytes to plasma caused by anticoagulants. The glucose concentrations during an OGTT in capillary blood are significantly higher than those in venous blood [mean of 1.7 mmol/L (30 mg/dL), equivalent to 20% to 25%], but the mean difference in fasting samples is only 0.1 mmol/L (2 mg/dL).

Although methods for glucose analysis exhibit low imprecision at the diagnostic decision limits of 7.0 mmol/L [(126 mg/dL), fasting] and 11.1 mmol/L [(200 mg/dL), postglucose load], the relatively large intraindividual biological variability (CVs of ~5% to 7%) may produce classification errors. On the basis of biological variation, glucose analysis should have analytical imprecision <3.4%, bias <2.6%, and total error <8.0%.1,2

Like a fasting glucose level >125 mg/dL, a two-hour postprandial glucose >200 mg/dL is virtually diagnostic of diabetes mellitus and obviates the need for a glucose tolerance test. An oral glucose tolerance test (OGTT) is not necessary in the setting of sufficiently high fasting and two-hour postprandial results.

Other causes of high glucose (serum or plasma) include nonfasting specimen; recent or current IV infusions of glucose; stress states such as myocardial infarct,5 brain damage, CVA,6 convulsive episodes, trauma, general anesthesia; Cushing disease; acromegaly; pheochromocytoma; glucagonoma; severe liver disease; pancreatitis; drugs (thiazide and other diuretics, corticoids, many others are reported to affect glucose).

The danger of hypoglycemia (low glucose) is lack of a steady supply of glucose to the brain (neuroglycopenia).

Causes of low glucose: Excess insulin, including rare insulin autoimmune hypoglycemia, surreptitious insulin injection, and sulfonylurea use; glycolysis in specimens overheated or old; serum permitted to stand on clot in red-top tube for chemistry profile. Very prompt removal of plasma and analysis is needed in cases of marked leukocytosis. Hypoglycemia should be confirmed by specimens drawn in fluoride tubes (gray-top tubes).

With hypoglycemia, symptoms must be correlated with plasma glucose.

Three major groups of hypoglycemia are defined: reactive, fasting, and surreptitious. The reactive group includes alimentary hyperinsulinism, prediabetic, endocrine deficiency, and idiopathic functional groups.7Postprandial hypoglycemia may occur after gastrointestinal surgery, and is described with hereditary fructose intolerance, galactosemia, and leucine sensitivity.

• Pancreatic islet cell tumors (insulinomas) − cause hypoglycemia in fasting individuals or after exercise. Measurement of simultaneous glucose, C-peptide, and insulin levels at the time of spontaneous hypoglycemia help to differentiate insulinoma from other conditions. The glucose:insulin ratio is useful in the diagnosis of insulinoma: insulin levels inappropriately increased for plasma glucose. An intravenous tolbutamide test with plasma glucose and serum insulin determinations may be used for evaluation of insulin-secreting islet cell tumors. The test is positive in approximately 75% of patients with these tumors.7 Glucagon and leucine stimulation tests are less frequently utilized.

• Extrapancreatic tumors−rare bulky fibromas, sarcomas, mesotheliomas, and carcinomas, including hepatoma and adrenal tumors

• Adrenal insufficiency (Addison disease), including congenital adrenal hyperplasia

• Hypopituitarism, isolated growth hormone or ACTH deficiency

• Starvation, malabsorption−but starvation does not cause hypoglycemia in normal persons

• Drugs including insulin (see above), oral hypoglycemic agents, and alcoholism, especially with starvation. Ethanolism is a common cause of hypoglycemia. Other drugs can depress glucose levels.

• Liver damage, including fulminant hepatic necrosis (hepatitis, toxicity), and severe congestive failure

• Tumor-induced hypoglycemia appears to be caused by increased production of an insulin-like substance (insulin-like growth factor II) by the tumor. This substance induces increased utilization of glucose by the peripheral tissues and the tumor, and impairs the counterregulatory effect of growth hormone by suppressing growth hormone secretion.8,9

Infancy and childhood: Infants with tremor, convulsions and/or respiratory distress should have stat glucose, particularly in the presence of maternal diabetes, hemolytic disease of the newborn (erythroblastosis fetalis); babies too large or small for gestational age should also have glucose level measured in the first 24 hours of life. A large number of entities relate to neonatal hypoglycemia, including glycogen storage diseases, galactosemia, hereditary fructose intolerance, ketotic hypoglycemia of infancy, fructose-1,6-diphosphatase deficiency, carnitine deficiency (a treatable disease presenting as Reye syndrome), and nesidioblastosis.

Specimen Requirements




1 mL

Minimum Volume

0.5 mL


Red-top tube or gel-barrier tube

Patient Preparation

Patient should fast for 12 hours.


Separate serum from cells within 45 minutes of collection. Label specimen as serum.

Storage Instructions

Maintain specimen at room temperature.

Stability Requirements



Room temperature

14 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Gross hemolysis; patient not fasting; blood stored overnight on clot; improper labeling

Clinical Information


1. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002 Mar; 48(3):436-472.11861436
2. American Diabetes Association. Clinical Practice Recommendations 2008. Diabetes Care. 2008; 31(Suppl 1).
3. Gerson B, Figoni MA. Clinical comparison of glucose quantitation methods. Arch Pathol Lab Med. 1985 Aug; 109(8):711-715. 2990377
4. Atkin SH, Dasmahapatra A, Jaker MA, Chorost MI, Reddy S. Fingerstick glucose determination in shock. Ann Intern Med. 1991 Jun 15; 114(12):1020-1024. 2029097
5. Madsen JK, Haunsoe S, Helquist S, et al. Prevalence of hyperglycaemia and undiagnosed diabetes mellitus in patients with acute myocardial infarction. Acta Med Scand. 1986; 220(4):329-332. 3799239
6. Berger L, Hakim AM. The association of hyperglycemia with cerebral edema in stroke. Stroke. 1986 Sep-Oct; 17(5):865-871. 3764956
7. Field JB. Hypoglycemia: A systematic approach to specific diagnosis. Hosp Pract (Off Ed). 1986 Sep 15; 21(9):187-194. 3018014
8. Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988 Dec 1; 319(22):1434-1440. 3185662
9. Axelrod L, Ron D. Insulin-like growth factor II and the riddle of tumor-induced hypoglycemia. N Engl J Med. 1988 Dec 1; 319:(22)1477-1479 (editorial).3185665


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
001032 Glucose, Serum 2345-7 001032 Glucose, Serum mg/dL 2345-7

For Providers

Please login to order a test.


© 2017  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2017, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at